Ana is a molecular biologist with a passion for discovery and communication. As a science writer, she looks for connecting the public, in particular patients and healthcare providers, with clear and quality information about the latest medical advances. Ana holds a Ph.D. in Biomedical Sciences from the University of Lisbon, Portugal, where she specialized in infectious diseases, epigenetics, and gene expression.
A combination of Zejula (niraparib) and Keytruda (pembrolizumab) is well-tolerated and has promising anti-tumor activity in women with ovarian carcinoma who ... Read more
Researchers have developed a two-step approach that harnesses the aging process of cells, allowing breast and ovarian cancers to be effectively ... Read more
DPX-Survivac combined with intermittent low-dose cyclophosphamide can generate significant anti-tumor immune responses that correlate with tumor regression in women with recurrent ... Read more
Maintenance therapy with Rubraca (rucaparib) tablets continues to benefit women with recurrent ovarian cancer after weighing in patients’ perceptions about their ... Read more
Combining Immunogen‘s mirvetuximab soravtansine, an investigational antibody-drug conjugate, with Avastin (bevacizumab) showed signs of favorable efficacy and demonstrated a manageable safety ... Read more
Myriad Genetics has submitted the first part of a premarket approval application with the U.S. Food and Drug Administration for myChoice HRD ... Read more
The Canadian government is warning that exposure of the female genital area to talc-containing products may be associated with ovarian cancer and that inhalation ... Read more
